Darusentan

Darusentan
Systematic (IUPAC) name

(2S)-2-(4,6-Dimethoxypyrimidin-2-yl)oxy-3-methoxy-3,3-di(phenyl)propanoic acid
Clinical data
Routes of administration	Oral
Pharmacokinetic data
Metabolism	Hepatic
Half-life	12.5 hours
Identifiers
CAS Registry Number	171714-84-4^Y
ATC code	None
PubChem	CID 177236
ChemSpider	154336^N
UNII	33JD57L6RW^N
ChEMBL	CHEMBL23261^N
Chemical data
Formula	C₂₂H₂₂N₂O₆
Molecular mass	410.42 g/mol
SMILES COC1=CC(=NC(=N1)O[C@H](C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)OC
InChI InChI=1S/C22H22N2O6/c1-27-17-14-18(28-2)24-21(23-17)30-19(20(25)26)22(29-3,15-10-6-4-7-11-15)16-12-8-5-9-13-16/h4-14,19H,1-3H3,(H,25,26)/t19-/m1/s1 ^N Key:FEJVSJIALLTFRP-LJQANCHMSA-N ^N
N (what is this?) (verify)

Darusentan (LU-135252; HMR-4005) is an endothelin receptor antagonist. Gilead Colorado, a subsidiary of Gilead Sciences,^[1] under license from Abbott Laboratories, is developing darusentan for the potential treatment of uncontrolled hypertension.

In June 2003, Myogen licensed the compound from Abbott for its application in the cancer field.^[2]

In May 2007, a randomized, double-blind, active control, parallel assignment, safety and efficacy phase III trial was initiated in subjects who had completed the maintenance period of the DAR-312 study.

Darusentan

References